4/2
04:00 pm
alks
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/2
04:00 pm
alks
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
Medium
Report
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference
4/1
07:22 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia [Yahoo! Finance]
Low
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia [Yahoo! Finance]
4/1
07:00 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Neutral
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
4/1
07:00 am
alks
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Neutral
Report
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
3/27
08:15 am
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a "buy" rating on the stock.
3/27
07:00 am
alks
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Low
Report
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
3/27
07:00 am
alks
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
Low
Report
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder
3/25
08:13 pm
alks
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? [Yahoo! Finance]
Low
Report
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? [Yahoo! Finance]
3/13
07:49 am
alks
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Royal Bank of Canada. They set a "sector perform" rating and a $40.00 price target on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Royal Bank of Canada. They set a "sector perform" rating and a $40.00 price target on the stock.
3/4
09:02 am
alks
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at UBS Group AG from a "sell" rating to a "neutral" rating. They now have a $38.00 price target on the stock, up previously from $21.00.
Medium
Report
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at UBS Group AG from a "sell" rating to a "neutral" rating. They now have a $38.00 price target on the stock, up previously from $21.00.
2/26
04:00 pm
alks
Alkermes to Participate in Upcoming Investor Conferences
Low
Report
Alkermes to Participate in Upcoming Investor Conferences
2/26
04:00 pm
alks
Alkermes to Participate in Upcoming Investor Conferences
Low
Report
Alkermes to Participate in Upcoming Investor Conferences
2/14
08:07 am
alks
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $32.00. They now have a "buy" rating on the stock.
2/13
10:01 pm
alks
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
2/13
07:38 am
alks
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Medium
Report
Alkermes plc (NASDAQ: ALKS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
2/12
03:14 pm
alks
Alkermes plc 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
Alkermes plc 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/12
07:35 am
alks
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 [Yahoo! Finance]
Low
Report
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 [Yahoo! Finance]
2/12
07:00 am
alks
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Low
Report
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
2/12
07:00 am
alks
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Low
Report
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
2/11
07:26 am
alks
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $40.00 price target on the stock.
Medium
Report
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $40.00 price target on the stock.
2/6
11:43 am
alks
Opioid Use Disorder Market Size Projected to Hit USD 9.02 Billion by 2032 - SNS Insider [Yahoo! Finance]
Low
Report
Opioid Use Disorder Market Size Projected to Hit USD 9.02 Billion by 2032 - SNS Insider [Yahoo! Finance]
2/5
04:00 pm
alks
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Low
Report
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
2/5
04:00 pm
alks
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025
Low
Report
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025